Department of Cardiovascular Medicine, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Department of Psychiatry, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
ESC Heart Fail. 2024 Oct;11(5):2967-2976. doi: 10.1002/ehf2.14886. Epub 2024 May 29.
Although patients with heart failure (HF) frequently experience considerable symptom burden and require significant care, most HF patients do not receive timely intervention due to the absence of a standardized method for identifying those in need of palliative care. The Needs Assessment Tool: Progressive Disease-Heart Failure (NAT: PD-HF) assesses the palliative care needs of patients with HF. However, its validity and reliability have yet to be fully examined. We aimed to assess the validity and reliability of the NAT: PD-HF in Japanese patients with HF.
We prospectively enrolled 106 consecutive patients with chronic HF admitted to our university hospital between February 2023 and July 2023. Their caregivers (n = 95) and healthcare providers (n = 17) were also included. The NAT: PD-HF was translated from English to Japanese using a forward-backward translation procedure and adapted based on Japanese cultural and medical backgrounds by our professional multidisciplinary team. We assessed the internal consistency of the Japanese NAT: PD-HF version with Cronbach's alpha coefficient and the inter-rater and test-retest reliabilities with Cohen's kappa coefficient. After using the tool, all participants were asked to complete a questionnaire about the tool to determine its validity.
The proportion of female patients in this study was 47 (44%). The median age was 72 years [interquartile range (IQR) 59-81]. The median time spent assessing the patients' and their caregivers' needs using the Japanese NAT: PD-HF was 14 min (IQR 12-17). The Cronbach's alpha coefficient was 0.82, and the minimum kappa coefficient was 0.77 for inter-rater reliability and 0.88 for test-retest reliability. In total, 103 patients (97%) and all caregivers responded that the tool was easy to understand. One hundred (94%) patients and 89 (94%) caregivers felt that the tool would improve the quality of care, and 102 (96%) patients and 91 (96%) caregivers indicated that the discussions using this tool allowed them to confide in all their burdens and care needs. All healthcare providers expressed that this tool is helpful in understanding the burden and care needs of both patients and caregivers comprehensively.
The NAT: PD-HF is a reliable and valid tool for Japanese patients with HF and their caregivers. This tool was very well accepted by patients, caregivers and healthcare providers to identify burdens and care needs.
尽管心力衰竭(HF)患者经常经历相当大的症状负担并需要大量护理,但由于缺乏识别需要姑息治疗的患者的标准化方法,大多数 HF 患者并未得到及时干预。需要评估工具:进展性疾病-心力衰竭(NAT:PD-HF)评估心力衰竭患者的姑息治疗需求。然而,其有效性和可靠性尚未得到充分检验。我们旨在评估 NAT:PD-HF 在日本心力衰竭患者中的有效性和可靠性。
我们前瞻性纳入了 2023 年 2 月至 2023 年 7 月期间我院连续收治的 106 例慢性 HF 患者及其 95 名照料者和 17 名医护人员。使用正向-反向翻译程序将 NAT:PD-HF 从英文翻译成日文,并由我们的专业多学科团队根据日本文化和医疗背景进行改编。我们使用 Cronbach's alpha 系数评估日本 NAT:PD-HF 版本的内部一致性,使用 Cohen's kappa 系数评估评分者间和测试-重测信度。使用工具后,所有参与者都被要求填写一份关于工具的问卷,以确定其有效性。
本研究中女性患者的比例为 47(44%)。中位年龄为 72 岁[四分位间距(IQR)59-81]。评估患者及其照料者需求的中位时间为 14 分钟(IQR 12-17)。Cronbach's alpha 系数为 0.82,评分者间最小 kappa 系数为 0.77,测试-重测信度为 0.88。共有 103 名(97%)患者和所有照料者表示该工具易于理解。100 名(94%)患者和 89 名(94%)照料者认为该工具将提高护理质量,而 102 名(96%)患者和 91 名(96%)照料者表示使用该工具的讨论使他们能够倾诉所有的负担和护理需求。所有医护人员都表示,该工具有助于全面了解患者和照料者的负担和护理需求。
NAT:PD-HF 是一种可靠且有效的工具,适用于日本心力衰竭患者及其照料者。该工具得到了患者、照料者和医护人员的广泛认可,可用于识别负担和护理需求。